Online first
Research paper
Published online: 2023-12-20

open access

Page views 260
Article views/downloads 52
Get Citation

Connect on Social Media

Connect on Social Media

Erratum has been published

Encorafenib plus cetuximab in patients with BRAFV600E-mutated metastatic colorectal cancer — Polish multicenter experience

Marek Gełej12, Patryk Zając23, Maria Dąbrowska4, Anna Drejws-Wątróbska5, Bogumiła Galińska6, Łukasz Galus7, Agnieszka Gwóźdź-Cieślik8, Katarzyna Hetman5, Maciej Kawecki9, Mateusz Malik10, Joanna Streb11, Katarzyna Wierzbicka12, Piotr Wiosek13, Barbara Radecka12


Introduction. The BRAF mutation occurs in 8–12% of patients with colorectal cancer. This is associated with unfavorable prognosis — in metastatic disease, median survival does not exceed one year. Molecularly targeted treatment — encorafenib with cetuximab — is the standard of care in cases of chemotherapy failure. 

Material and methods. Medical data of 18 patients treated with encorafenib and cetuximab in 2021–2023 in 10 oncology centers in Poland were assessed. We analyzed clinical, pathomorphological, and molecular factors, as well as the effectiveness and safety of treatment. 

Results. The median age in the group was 63 years. Patients with metastases limited to one location predominated (78%). Treatment with encorafenib and cetuximab was used not only in the third (in 50% of patients) or fourth (in 28%) lines of treatment but also in the second (in 22%). The objective response rate was 29.4%, and the disease control rate was 76.4%. The median progression-free survival was 7.1 months. Four patients (22%) had a response lasting over 12 months. 

Conclusions. The results of the analysis confirmed the efficacy and safety of targeted treatment with encorafenib and cetuximab in patients with metastatic colorectal cancer with the BRAFV600E mutation, known from other studies.

Article available in PDF format

View PDF Download PDF file


  1. Global Burden of Disease Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. JAMA Oncol. 2022; 8(3): 420–444.
  2. Krajowy Rejestr Nowotworów. (31.07.2023).
  3. Cervantes A, Adam R, Roselló S, et al. ESMO Guidelines Committee. Electronic address: Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(1): 10–32.
  4. Zeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023; 7(1): 16.
  5. Grothey A, Fakih M, Tabernero J. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Ann Oncol. 2021; 32(8): 959–967.
  6. Martinelli E, Arnold D, Cervantes A, et al. European expert panel consensus on the clinical management of BRAF-mutant metastatic colorectal cancer. Cancer Treat Rev. 2023; 115: 102541.
  7. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–247.
  8. Kopetz S, Grothey A, Tabernero J, et al. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. N Engl J Med. 2020; 382(9): 876–877.
  9. Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. J Clin Oncol. 2021; 39(4): 273–284.
  10. Boccaccino A, Borelli B, Intini R, et al. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO Open. 2022; 7(3): 100506.
  11. Montes AF, Ros J, Graña B, et al. Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: Confidence study. Journal of Clinical Oncology. 2023; 41(4_suppl): 126–126.
  12. Stintzing S, Heyde Ev, Wierecky J, et al. Disease characteristics and clinical practice of BRAF V600E-mutant metastatic colorectal cancer treatment: Baseline analysis of patients enrolled in the BERING CRC study. J Clin Oncol. 2023; 41(4_suppl): 34–34.
  13. Corcoran RB, Atreya CE, Falchook GS, et al. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015; 33(34): 4023–4031.
  14. Corcoran RB, André T, Atreya CE, et al. Combined BRAF, EGFR, and MEK Inhibition in Patients with -Mutant Colorectal Cancer. Cancer Discov. 2018; 8(4): 428–443.
  15. Tampellini M, Di Maio M, Baratelli C, et al. Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit. Clin Colorectal Cancer. 2017; 16(4): 372–376.
  16. Martinelli E, Cremolini C, Mazard T, et al. Real-world first-line treatment of patients with BRAF-mutant metastatic colorectal cancer: the CAPSTAN CRC study. ESMO Open. 2022; 7(6): 100603.